Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Treatment Outcomes for Osteochondritis Dissecans of the Knee, Elbow and Ankle (OCD-MULTI): A Cohort Study

sunnuntai 8. marraskuuta 2026 päivittänyt: Liu Zhenlong, Peking University Third Hospital

Treatment Outcomes for Osteochondritis Dissecans of the Knee, Elbow and Ankle in Patients Aged 6 to 18 Years: An Ambidirectional Cohort Study

This is a single-centre, non-randomized, observational, bidirectional (retrospective and prospective) cohort study conducted at the Department of Sports Medicine of Peking University Third Hospital, Beijing. It enrols patients aged 6 to 18 years with magnetic resonance imaging (MRI)-confirmed osteochondritis dissecans (OCD) of the knee, elbow or ankle. The planned first analysis cohort comprises 177 participants: a retrospective cohort of 77 patients treated between January 2016 and 26 October 2025, and a prospective cohort of at least 100 participants enrolled consecutively from 27 October 2025 under an open-ended (rolling) recruitment policy with no fixed recruitment closing date, contingent on continued ethics approval, cohort infrastructure and funding; the registered completion date is maintained as an estimated date and updated as rolling enrolment proceeds.

Based on the treatment actually received, participants are classified into a conservative treatment group or a surgical treatment group; the surgical group is further categorized into six standard techniques. All comparisons are stratified by the affected joint.

The primary outcomes at 24 months are: (1) the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score based on MRI in surgically treated participants; and (2) MRI-assessed stage regression in conservatively treated participants, using the Hefti staging for the knee, a five-stage T2-weighted MRI staging for the elbow (capitellum), and the Berndt-Harty classification (grades I, IIA, IIB, III and IV) for the ankle. Secondary outcomes are validated joint-specific functional measures (knee: IKDC Subjective Knee Form, Lysholm Knee Score and Tegner Activity Scale; elbow: Mayo Elbow Performance Score and QuickDASH; ankle: Foot and Ankle Outcome Score and AOFAS Ankle-Hindfoot Scale), pain on the visual analogue scale, reoperation and adverse events. All MRIs are independently read by radiologists/orthopaedic clinicians blinded to treatment assignment. Participants are followed for 24 months. The first locked prospective cohort (2030-12-31) forms the confirmatory analysis; participants enrolled after the first data-lock are analysed in prespecified periodic updates.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Design: This is a single-centre, non-randomized, observational ambidirectional cohort combining a retrospective cohort (patients treated from 1 January 2016 to 26 October 2025) with a consecutively enrolled prospective cohort (first participant enrolled 27 October 2025). The study is set in the Department of Sports Medicine of Peking University Third Hospital, and will be reported following the STROBE guideline. No treatment is assigned by the study; all treatment decisions are made by the treating clinician and patient according to current guidelines and individual circumstances, before and independently of study participation.

Participants: Males and females aged 6 to 18 years (inclusive) with a clinical and MRI diagnosis of OCD of the knee, elbow or ankle who receive treatment at the department are eligible. The prospective cohort uses non-probability consecutive sampling: every eligible, consenting patient is screened in chronological order and enrolled, with no fixed enrolment closing date. The retrospective cohort is identified from the institutional electronic medical record using the same eligibility criteria, with data extracted from existing records under a separate ethics approval.

Exposure definition: Participants are classified by the treatment actually received. Conservative management may include activity/sports restriction, bracing or short-term immobilization, protected weight-bearing, supervised physiotherapy, therapeutic ultrasound, analgesic/anti-inflammatory medication and traditional Chinese medicine. Surgical treatment comprises one of six standard procedures: (1) arthroscopic debridement; (2) fragment internal fixation; (3) subchondral/retroarticular drilling; (4) microfracture; (5) autogenous osteochondral transplantation; and (6) allogeneic osteochondral transplantation. Participants receiving multiple procedures are classified by the primary reconstructive procedure.

Imaging and staging: All joints undergo a standardized institutional MRI protocol at baseline and at 3, 6, 12 and 24 months. Lesion stability is staged on MRI using the Hefti system (stages I-V) for the knee, a five-stage T2-weighted MRI staging for the capitellum (I: normal contour with spotted high signal; II: more extensive high signal; III: discontinuity of the chondral surface without a high-signal interface; IV: a high-signal line separating the lesion; V: displacement or defect), and the Berndt-Harty classification for the talus (I: intact cartilage with subchondral injury; IIA: subchondral cyst; IIB: transverse fracture line without fragment; III: non-displaced fragment surrounded by fluid; IV: displaced fragment). MRIs are read independently by two readers blinded to treatment, with disagreement resolved by consensus or a third reader; inter-rater reliability is reported using the intraclass correlation coefficient.

Outcomes and schedule: The primary structural outcome is the 24-month MOCART score (0-100; higher scores indicate better morphological repair, >70 good and >85 excellent) in surgical participants, and MRI stage regression in conservative participants. Joint-specific functional scales and the pain VAS are recorded at baseline, treatment day, 7 days, and 3, 6, 12 and 24 months. Adverse and serious adverse events, complications, reoperation and concomitant treatment are monitored from treatment initiation through the last visit. Height and weight are measured at baseline.

Covariates: Baseline data include age, sex, height, weight and body mass index, affected side and joint, sports type/frequency/duration and trigger, comorbidities and concomitant medication. Skeletal maturity (immature versus mature) is determined from age and, when needed, radiographs and clinical physeal assessment. Lesion size (cm2 on MRI), intra-articular location and MRI stability are assessed by blinded evaluators. Lesion stability and skeletal maturity are prespecified effect modifiers; lesion size and joint are additional exploratory effect modifiers.

Governance: The study is sponsored by Peking University Third Hospital and overseen by a study management group chaired by the principal investigator, which reviews enrolment, data quality and adverse events at least annually and at every ethics renewal. Continuing recruitment is conditional on renewed ethics approval, maintained infrastructure and funding; the study will stop enrolling if approval or funding ceases, if the protocol can no longer be delivered to standard, or when a final analysis plan is adopted, without affecting follow-up of participants already enrolled.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

177

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kiina, 100191
        • Rekrytointi
        • Peking University Third Hospital
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

6 vuotta - 18 vuotta (Lapsi, Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

This study aims to establish a cohort for the treatment of osteochondritis dissecans (OCD) of the knee, elbow and ankle joint. The target population consists of patients with OCD who have been diagnosed through clinical and imaging (MRI) examinations and are treated at the Department of Sports Medicine of Peking University Third Hospital. The age range is from 6 years old to 18 years old (inclusive).

Kuvaus

Inclusion Criteria:

  • Diagnosis of osteochondritis dissecans of the knee;
  • No participation in any other clinical trial within the past 3 months;
  • Voluntary participation, provision of signed informed consent, and ability to comply with the clinical follow-up schedule.

Exclusion Criteria:

  • Regular use of sedatives, hypnotics, anxiolytics, or other addictive substances;
  • Presence of severe primary diseases in the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems, or psychiatric disorders;
  • Inability or unwillingness to undergo prolonged and intensive postoperative rehabilitation;
  • Females who are planning pregnancy within the next 12 months, or who are currently breastfeeding or pregnant;
  • Individuals with specific beliefs or restrictions that preclude the use of medical devices derived from porcine sources (as some grafts/devices are porcine-derived);
  • Contraindications to Magnetic Resonance Imaging (MRI) examination;
  • Individuals with psychiatric disorders impairing decision-making capacity, or any other condition deemed by the investigator to make participation inadvisable.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: COHORT
  • Aikanäkymät: OTHER

Kohortit ja interventiot

Ryhmä/Kohortti
Interventio / Hoito
Conservative Management Cohort

Patients in this cohort receive non-surgical management, which may include activity restriction, braces/orthoses, immobilizers/casts, therapeutic ultrasound, analgesics, anti-inflammatory medications, and/or Traditional Chinese Medicine (TCM).

This is not an intervention assigned by the study. It encompasses the spectrum of standard conservative and surgical treatments that participants may receive as part of independent clinical care. The specific treatment each participant receives is documented and used to define the study cohorts for observational comparison.

Surgical Treatment Cohort

Patients who undergo any of the following standard surgical procedures as part of their routine clinical care: joint debridement, internal fixation, retroarticular drilling, microfracture, autogenous transplantation, or allograft transplantation.

This is not an intervention assigned by the study. It encompasses the spectrum of standard conservative and surgical treatments that participants may receive as part of independent clinical care. The specific treatment each participant receives is documented and used to define the study cohorts for observational comparison.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score in surgical treatment cohort
Aikaikkuna: preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.

In this study, the MOCART score quantitatively assesses cartilage/osteochondral repair on MRI across nine dimensions, including integrity of the repaired tissue, surface appearance, signal intensity and integration with surrounding tissue. The total score ranges from 0 to 100; higher scores indicate better morphological repair, with scores >70 defined as good and >85 as excellent. This primary outcome applies to surgically treated participants across the knee, elbow and ankle.

preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.
MRI stage regression in conservative treatment cohort
Aikaikkuna: preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.

Stage regression of the OCD lesion on serial MRI in conservatively treated participants, assessed by readers blinded to treatment using the joint-specific validated system: the Hefti staging (stages I-V) for the knee, a five-stage T2-weighted MRI staging (stages I-V) for the elbow capitellum, and the Berndt-Harty classification (grades I, IIA, IIB, III and IV) for the talus. Stage regression (a decrease in stage from baseline) indicates structural healing/stabilization and is summarized as the proportion with regression and the change in stage at 24 months.

preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Tegner Activity Scale
Aikaikkuna: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

It is a one-dimensional scale ranging from 0 to 10, used to assess the activity level of patients in terms of sports and daily work. The higher the score, the higher the activity level of knee joint. High score (8-10 points): Indicates the level of competitive sports, with extremely high requirements for the knee joint. Medium score (4-7 points): Represents recreational sports and physical labor, which is the level of most active people. Low score (0-3 points): Represents daily life and sedentary work, with a lower load on the knee joint.

preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
International Knee Documentation Committee (IKDC)-2000
Aikaikkuna: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

It can comprehensively assess the knee joint's functionality, consisting of 18 questions, covering three dimensions: symptoms, sports activity function, and daily activity function. The higher the score, the better the knee joint's functionality and the fewer the symptoms. Generally, a score of >90 indicates excellent function, while a score of <70 indicates significant functional impairment. The minimum clinically important difference is approximately 10-12 points.

preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
Lysholm Knee Score
Aikaikkuna: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

It can assess specific symptoms and functional impairments of the knee joint, and has particular advantages in reflecting instability and limitations in daily activities. It consists of 8 items, with a total score of 100. The higher the score, the better the function. Function classification (widely accepted standard): Excellent: 95 - 100 points; Good: 84 - 94 points; Average: 65 - 83 points; Poor: < 65 points.

preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
Visual Analog Scale
Aikaikkuna: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

It can quantify the intensity of subjective pain and is the simplest and most direct method for pain assessment. It is usually a horizontal line 10 centimeters long, with "no pain" marked at the left end (0 points) and "the most intense pain" marked at the right end (10 points). The patient marks their own sensation on the line. 0 points: No pain. 1-3 points: Mild pain (not affecting sleep). 4-6 points: Moderate pain (affects sleep but is tolerable). 7-10 points: Severe pain (extremely unbearable, seriously affecting sleep and daily life).

preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
Mayo Elbow Performance Score (MEPS)
Aikaikkuna: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

The Mayo Elbow Performance Score (MEPS) is a standardized clinician- and patient-reported composite outcome measure used to assess elbow-specific symptoms and functional impairment. It evaluates four domains: pain (0-45 points), range of motion/flexion-extension arc (0-20 points), joint stability (0-10 points), and ability to perform daily activities (0-25 points; combing hair, feeding, hygiene, donning shirt, donning shoes). The total score ranges from 0 to 100, with higher scores indicating better elbow function and less disability. Function classification: Excellent: 90-100 points; Good: 75-89 points; Fair: 60-74 points; Poor: <60 points.

preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
Quick DASH
Aikaikkuna: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

The Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) is a shortened, validated patient-reported outcome measure assessing upper-extremity symptoms and functional impairment. It consists of 11 items covering difficulty with physical activities, pain, tingling, sleep disturbance, and limitations in work and social activities. Each item is rated on a 5-point Likert scale from 1 (no difficulty/no symptom) to 5 (unable/extreme symptom). At least 10 of 11 items must be completed for scoring. The score is transformed to a 0-100 scale using the formula: [(mean of completed items - 1) × 25]. The total score ranges from 0 to 100, where 0 indicates no disability and 100 indicates the most severe upper-extremity disability. Higher scores represent worse function.

preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
Foot and Ankle Outcome Score (FAOS)
Aikaikkuna: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

The Foot and Ankle Outcome Score (FAOS) is a patient-reported outcome measure assessing foot- and ankle-related pain, symptoms, daily function, sports/recreation function, and quality of life. It consists of 42 items divided into five subscales: Pain (9 items), Other Symptoms (7 items), Activities of Daily Living (17 items), Sport and Recreation (5 items), and Foot- and Ankle-Related Quality of Life (4 items). Each item is scored on a 5-point Likert scale from 0 (no problem) to 4 (extreme problem). Each subscale is normalized to a 0-100 scale, where 100 indicates no symptoms or functional limitation and 0 indicates the worst possible state. Higher subscale scores indicate better foot and ankle function. A total FAOS score is not routinely derived; subscales are reported separately.

preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale
Aikaikkuna: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

The American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale is a clinician- and patient-assessed composite measure evaluating clinical status of the ankle and hindfoot. It includes 9 items in three domains: Pain (1 item, 0-40 points), Function (7 items, 0-50 points; activity limitation/support, walking distance, walking surfaces, gait, sagittal motion, hindfoot motion, stability), and Alignment (1 item, 0-10 points). The total score ranges from 0 to 100, with 100 indicating no pain, full function, and good alignment. Higher scores indicate better clinical outcome. Commonly used classification: Excellent 90-100; Good 75-89; Fair 50-74; Poor <50.

preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Pituus
Aikaikkuna: Preoperatiivisesti
Preoperatiivisesti
Paino
Aikaikkuna: Preoperatiivisesti
Preoperatiivisesti
AE/SAE
Aikaikkuna: postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

This study will systematically monitor and record all adverse events and serious adverse events that occur from the start of treatment until the last follow-up. Adverse events refer to any adverse medical events that occur in patients after receiving treatment. These include, but are not limited to, common complications related to surgery, failure of cartilage repair, joint stiffness, and activity impairment. Serious adverse events include situations that result in death, endanger life, require hospitalization, cause significant functional impairment, or other important medical events.

postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 27. lokakuuta 2025

Ensisijainen valmistuminen (Arvioitu)

Sunnuntai 31. joulukuuta 2028

Opintojen valmistuminen (Arvioitu)

Tiistai 31. joulukuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Lauantai 6. joulukuuta 2025

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 26. helmikuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Perjantai 27. helmikuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 12. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Sunnuntai 8. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • BYSYDL2025034
  • Peking University Third Hospit (Muu apuraha/rahoitusnumero: BYSYDL2025034)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa